Andreas Bjorefeldt
Overview
Explore the profile of Andreas Bjorefeldt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forsberg M, Zhou D, Jalali S, Faravelli G, Seth H, Bjorefeldt A, et al.
J Neurochem
. 2024 Aug;
169(1):e16209.
PMID: 39164935
It is well recognized that changes in the extracellular concentration of calcium ions influence the excitability of neurons, yet what mechanism(s) mediate these effects is still a matter of debate....
2.
Slaviero A, Gorantla N, Simkins J, Crespo E, Ikefuama E, Tree M, et al.
Neurophotonics
. 2024 Apr;
11(2):024208.
PMID: 38559366
Significance: Luminopsins (LMOs) are bioluminescent-optogenetic tools with a luciferase fused to an opsin that allow bimodal control of neurons by providing both optogenetic and chemogenetic access. Determining which design features...
3.
Engstrom Ruud L, Font-Girones F, Zajdel J, Kern L, Teixidor-Deulofeu J, Manneras-Holm L, et al.
Cell Rep
. 2024 Mar;
43(4):113960.
PMID: 38507407
GFRAL-expressing neurons actuate aversion and nausea, are targets for obesity treatment, and may mediate metformin effects by long-term GDF15-GFRAL agonism. Whether GFRAL neurons acutely regulate glucose and energy homeostasis is,...
4.
Bjorefeldt A, Murphy J, Crespo E, Lambert G, Prakash M, Ikefuama E, et al.
Neurophotonics
. 2024 Mar;
11(2):021005.
PMID: 38450294
Significance: Bioluminescent optogenetics (BL-OG) offers a unique and powerful approach to manipulate neural activity both opto- and chemogenetically using a single actuator molecule (a LuMinOpsin, LMO). Aim: To further enhance...
5.
Slaviero A, Gorantla N, Simkins J, Crespo E, Ikefuama E, Tree M, et al.
bioRxiv
. 2023 Dec;
PMID: 38045286
Significance: Luminopsins (LMOs) are bioluminescent-optogenetic tools with a luciferase fused to an opsin that allow bimodal control of neurons by providing both optogenetic and chemogenetic access. Determining which design features...
6.
Bjorefeldt A, Murphy J, Crespo E, Lambert G, Prakash M, Ikefuama E, et al.
bioRxiv
. 2023 Jul;
PMID: 37425735
Significance: Bioluminescent optogenetics (BL-OG) offers a unique and powerful approach to manipulate neural activity both opto- and chemogenetically using a single actuator molecule (a LuMinOpsin, LMO). Aim: To further enhance...
7.
Prakash M, Murphy J, St Laurent R, Friedman N, Crespo E, Bjorefeldt A, et al.
Commun Biol
. 2022 Jan;
5(1):33.
PMID: 35017641
Understanding percepts, engrams and actions requires methods for selectively modulating synaptic communication between specific subsets of interconnected cells. Here, we develop an approach to control synaptically connected elements using bioluminescent...
8.
Crespo E, Bjorefeldt A, Prakash M, Hochgeschwender U
J Vis Exp
. 2021 Aug;
(174).
PMID: 34424228
Bioluminescence - light emitted by a luciferase enzyme oxidizing a small molecule substrate, a luciferin - has been used in vitro and in vivo to activate light-gated ion channels and...
9.
Crespo E, Prakash M, Bjorefeldt A, Medendorp W, Shaner N, Lipscombe D, et al.
STAR Protoc
. 2021 Jul;
2(3):100667.
PMID: 34286295
Bioluminescent optogenetics (BL-OG) allows activation of photosensory proteins, such as opsins, by either fiberoptics or by administering a luciferin. BL-OG thus confers both optogenetic and chemogenetic access within the same...
10.
Medendorp W, Bjorefeldt A, Crespo E, Prakash M, Pal A, Waddell M, et al.
iScience
. 2021 Mar;
24(3):102157.
PMID: 33665575
In genetic and pharmacological models of neurodevelopmental disorders, and human data, neural activity is altered within the developing neocortical network. This commonality begs the question of whether early enhancement in...